Aliskiren hemifumarate

Aliskiren Hemifumarate is an orally active nonpeptide renin inhibitor with antihypertensive activity. Aliskiren selectively binds to the S3 sub-pocket of renin, an enzyme in the renin-angiotensin-aldosterone system (RAAS) that is responsible for converting angiotensinogen to angiotensin I (AT I). By inhibiting the activity of renin, the conversion to AT I is prevented, which in turn prevents the conversion of AT I to AT II. This prevents arterial vasoconstriction by AT II and inhibits the production of aldosterone by AT II. As aldosterone causes re-uptake of sodium and water and eventually an increase in extracellular volume, aliskiren is able to prevent the effects that contribute to an increase in blood pressure. Its therapeutic use is listed as antihypertensives and cardiovascular. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Aliskiren fumarate, Enviage, Riprazo and Sprimeo. Its PubChem CID is 6918427.